February 2018 - Biologics by McKesson

ERLEADA™ (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, available for order at Biologics by McKesson

Feb 21, 2018 | Press Release

CARY, N.C. (February 21, 2018) —Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, has been selected by the Janssen Pharmaceutical Companies of Johnson & Johnson1 to be in the limited distribution network for...

ERLEADA™ (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, available for order at Biologics by McKesson

Recent Posts

Archives